New pooled analysis adds weight to edoxaban's benefits in VTE after orthopaedic surgery
This article was originally published in Scrip
A pooled analysis of existing Asian data for Daiichi Sankyo's antithrombotic edoxaban has provided further evidence of the efficacy and safety of the oral direct Factor Xa inhibitor in the orthopaedic setting compared with the current standard of care, enoxaparin sodium.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.